<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="53059"><DrugName>linifanib</DrugName><DrugNamesKey><Name id="42910517">linifanib</Name></DrugNamesKey><DrugSynonyms><Name><Value>tyrosine kinase inhibitors (cancer), Abbott</Value></Name><Name><Value>ABT-869</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AL-39324</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>linifanib</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>RG-3635</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>796967-16-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="13601">Abbott Laboratories</CompanyOriginator><CompaniesSecondary><Company id="13601">Abbott Laboratories</Company><Company id="19453">Genentech Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="53059" type="Drug"><TargetEntity id="396702" type="siDrug">Linifanib</TargetEntity></SourceEntity><SourceEntity id="13601" type="Company"><TargetEntity id="4295903265" type="organizationId">Abbott Laboratories</TargetEntity></SourceEntity><SourceEntity id="19453" type="Company"><TargetEntity id="4295912132" type="organizationId">Genentech Inc</TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"/><TargetEntity id="D002289" type="MeSH"/><TargetEntity id="-1730468577" type="omicsDisease"/><TargetEntity id="612" type="siCondition"/></SourceEntity><SourceEntity id="1272" type="ciIndication"><TargetEntity id="D46" type="ICD10"/><TargetEntity id="10028533" type="MEDDRA"/><TargetEntity id="D011289" type="MeSH"/><TargetEntity id="-376765165" type="omicsDisease"/><TargetEntity id="711" type="siCondition"/></SourceEntity><SourceEntity id="1731" type="ciIndication"><TargetEntity id="D015470" type="MeSH"/><TargetEntity id="519" type="ORPHANET"/><TargetEntity id="-1550871001" type="omicsDisease"/><TargetEntity id="686" type="siCondition"/></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"/><TargetEntity id="88673" type="ORPHANET"/><TargetEntity id="-1116061312" type="omicsDisease"/><TargetEntity id="1973" type="siCondition"/></SourceEntity><SourceEntity id="4250" type="ciIndication"><TargetEntity id="10050513" type="MEDDRA"/><TargetEntity id="3229" type="siCondition"/></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="989" type="ciIndication"><TargetEntity id="10061451" type="MEDDRA"/><TargetEntity id="D015179" type="MeSH"/><TargetEntity id="-1280257855" type="omicsDisease"/><TargetEntity id="594" type="siCondition"/></SourceEntity><SourceEntity id="3808" type="Action"><TargetEntity id="1704" type="Mechanism">KIT (C-KIT) Inhibitors</TargetEntity><TargetEntity id="5665" type="Mechanism">KIT (C-KIT) (Asp816Val Mutant) Inhibitors</TargetEntity><TargetEntity id="3405" type="Mechanism">Anti-c-KIT</TargetEntity></SourceEntity><SourceEntity id="3154" type="Action"><TargetEntity id="4956" type="Mechanism">Anti-M-CSF</TargetEntity><TargetEntity id="4836" type="Mechanism">Anti-Colony Stimulating Factor 1 Receptor (CSF1R)</TargetEntity><TargetEntity id="2314" type="Mechanism">CSF1R (c-FMS) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3806" type="Action"><TargetEntity id="1910" type="Mechanism">Anti-CD135 (flt-3)</TargetEntity><TargetEntity id="1628" type="Mechanism">Flt3 (FLK2/STK1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3850" type="Action"><TargetEntity id="1627" type="Mechanism">VEGFR-3 (FLT4) Inhibitors</TargetEntity><TargetEntity id="2518" type="Mechanism">Anti-VEGFR-3 (FLT4)</TargetEntity></SourceEntity><SourceEntity id="3846" type="Action"><TargetEntity id="1308" type="Mechanism">VEGFR-1 (Flt-1) Inhibitors</TargetEntity><TargetEntity id="2609" type="Mechanism">Anti-VEGFR-1 (Flt-1)</TargetEntity></SourceEntity><SourceEntity id="61" type="Action"><TargetEntity id="885" type="Mechanism">Angiogenesis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3848" type="Action"><TargetEntity id="1309" type="Mechanism">VEGFR-2 (FLK-1/KDR) Inhibitors</TargetEntity><TargetEntity id="1786" type="Mechanism">Anti-VEGFR-2 (KDR)</TargetEntity></SourceEntity><SourceEntity id="PTGT-00510" type="ciTarget"><TargetEntity id="174052253714363" type="siTarget">Macrophage colony-stimulating factor 1 receptor</TargetEntity><TargetEntity id="471" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-00762" type="ciTarget"><TargetEntity id="212861059123223" type="siTarget">Receptor-type tyrosine-protein kinase FLT3</TargetEntity><TargetEntity id="7001" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-01208" type="ciTarget"><TargetEntity id="87400752538153" type="siTarget">Mast/stem cell growth factor receptor Kit</TargetEntity><TargetEntity id="441" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-01938" type="ciTarget"><TargetEntity id="62129556823213" type="siTarget">Vascular endothelial growth factor receptor 1</TargetEntity><TargetEntity id="810" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-01939" type="ciTarget"><TargetEntity id="172853942537913" type="siTarget">Vascular endothelial growth factor receptor 2</TargetEntity><TargetEntity id="811" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-01940" type="ciTarget"><TargetEntity id="108789232923243" type="siTarget">Vascular endothelial growth factor receptor 3</TargetEntity><TargetEntity id="812" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="1272">Myelodysplastic syndrome</Indication><Indication id="1731">Acute myelogenous leukemia</Indication><Indication id="1767">Hepatocellular carcinoma</Indication><Indication id="4250">Metastatic renal cell carcinoma</Indication><Indication id="49">Breast tumor</Indication><Indication id="651">Cancer</Indication><Indication id="989">Colorectal tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="3154">CSF-1 antagonist</Action><Action id="3806">Flt3 tyrosine kinase inhibitor</Action><Action id="3808">Kit tyrosine kinase inhibitor</Action><Action id="3850">VEGF-3 receptor antagonist</Action><Action id="3848">VEGF-2 receptor antagonist</Action><Action id="3846">VEGF-1 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="61">Angiogenesis inhibitor</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-08-30T15:38:39.000Z</LastModificationDate><ChangeDateLast>2018-06-11T00:00:00.000Z</ChangeDateLast><AddedDate>2005-04-20T13:03:38.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="13601" linkType="Company"&gt;Abbott&lt;/ulink&gt;   was developing linifanib (RG-3635; ABT-869), a small-molecule, multi-targeted inhibitor of  VEGF and PDGF family receptor tyrosine kinases,  for the potential oral treatment of various cancers, including hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), breast cancer, colorectal cancer (CRC) and renal cell carcinoma (RCC)  [&lt;ulink linkID="593433" linkType="Reference"&gt;593433&lt;/ulink&gt;], [&lt;ulink linkID="596245" linkType="Reference"&gt;596245&lt;/ulink&gt;], [&lt;ulink linkID="685691" linkType="Reference"&gt;685691&lt;/ulink&gt;], [&lt;ulink linkID="808616" linkType="Reference"&gt;808616&lt;/ulink&gt;], [&lt;ulink linkID="983719" linkType="Reference"&gt;983719&lt;/ulink&gt;], [&lt;ulink linkID="1049733" linkType="Reference"&gt;1049733&lt;/ulink&gt;]. However, all ongoing publicly listed trials for linifanib were terminated or completed in 2H12, and the program was no longer listed on the company's November 2012 pipeline [&lt;ulink linkID="1347508" linkType="Reference"&gt;1347508&lt;/ulink&gt;], [&lt;ulink linkID="1347496" linkType="Reference"&gt;1347496&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2009, a phase III trial in HCC began. However in July 2012, the study was terminated following a recommendation from the Independent Data Monitoring Committee [&lt;ulink linkID="1074723" linkType="Reference"&gt;1074723&lt;/ulink&gt;]. In August 2007, a phase II trial in NSCLC was initiated. In June 2008, a NSCLC combination study commenced. Both studies were completed in June and April 2012, respectively [&lt;ulink linkID="829114" linkType="Reference"&gt;829114&lt;/ulink&gt;], [&lt;ulink linkID="1030118" linkType="Reference"&gt;1030118&lt;/ulink&gt;]. By October 2008, phase II trials for breast cancer and CRC were underway [&lt;ulink linkID="957720" linkType="Reference"&gt;957720&lt;/ulink&gt;]. The breast cancer and CRC trials were completed in March 2010 and May 2012, respectively [&lt;ulink linkID="1030112" linkType="Reference"&gt;1030112&lt;/ulink&gt;], [&lt;ulink linkID="1030114" linkType="Reference"&gt;1030114&lt;/ulink&gt;]. In July 2007, a phase II trial in RCC was initiated; the study was completed in July 2012 [&lt;ulink linkID="809181" linkType="Reference"&gt;809181&lt;/ulink&gt;]. In July 2009, US and EU submissions had been expected post-2012 [&lt;ulink linkID="1028756" linkType="Reference"&gt;1028756&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="19453" linkType="Company"&gt;Genentech&lt;/ulink&gt; (a wholly owned subsidiary of &lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt;) was collaborating with Abbott in the development of linifanib [&lt;ulink linkID="808616" linkType="Reference"&gt;808616&lt;/ulink&gt;]; however, in December  2009, Roche announced it had reverted the program back to Abbott [&lt;ulink linkID="1074105" linkType="Reference"&gt;1074105&lt;/ulink&gt;]. The companies were also developing linifanib for the potential treatment of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In January 2006, a phase I trial was initiated involving patients with refractory or relapsed AML and MDS  [&lt;ulink linkID="685691" linkType="Reference"&gt;685691&lt;/ulink&gt;]; however, no development has been reported since this time.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In July 2009, US and EU submissions were expected to be made post-2012 [&lt;ulink linkID="1028756" linkType="Reference"&gt;1028756&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Hepatocellular carcinoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In October 2009, a randomized, open-labeled, phase III trial (&lt;ulink linkID="61697" linkType="Protocol"&gt;NCT01009593&lt;/ulink&gt;; M10-963) began in patients (expected n = 900) with advanced HCC in the US, Europe, Japan and Asia. The trial would evaluate the efficacy and tolerability of linifanib 17.5 mg po, with &lt;ulink linkID="29831" linkType="Drug"&gt;sorafenib&lt;/ulink&gt;, with the primary endpoint being overall survival. The trial was expected to complete in February 2012. In February 2011, the trial was expanded to additional countries, including Canada, Australia and New Zealand, Russia, Egypt, Mexico, Argentina, Chill and Puerto Rico. In June 2011, the trial was recruiting participants. However, in July 2012, the study was terminated following recommendation from the Independent Data Monitoring Committee [&lt;ulink linkID="1074723" linkType="Reference"&gt;1074723&lt;/ulink&gt;]. In January 2013, data from this trial were presented at ASCO's Gastrointestinal Cancer Symposium in San Francisco, CA. Median overall survival was 9.1 months on linifanib and 9.8 months on sorafenib. The median time to progression was 5.4 and 4.0 months for linifanib and sorafenib, respectively. Grade 3/4 adverse events (AEs), serious AEs and AEs leading to discontinuations, dose interruptions and reductions were more frequent for linifanib compared with sorafenib (p &amp;lt; 0.001). In this trial, the predefined superiority and non-inferiority overall survival boundaries were not met for linifanib [&lt;ulink linkID="1363518" linkType="Reference"&gt;1363518&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In August 2007, a non-randomized, open-label, uncontrolled, phase II trial (&lt;ulink linkID="39089" linkType="Protocol"&gt;NCT00517920&lt;/ulink&gt;; M06-879) was initiated in patients (expected n = 44) with HCC in the US, Canada, China and Singapore. The primary endpoint was PFS at 16 weeks. The trial was completed in  June 2012  [&lt;ulink linkID="827892" linkType="Reference"&gt;827892&lt;/ulink&gt;], [&lt;ulink linkID="1000652" linkType="Reference"&gt;1000652&lt;/ulink&gt;]; enrollment was completed by September 2008 [&lt;ulink linkID="1000652" linkType="Reference"&gt;1000652&lt;/ulink&gt;]. In May 2009, interim data were reported at the 45th ASCO meeting in Orlando, FL. Interim data were available for 34 of 44 enrolled patients; 73.5% had received no prior systemic therapy. Progression-free rate at 16 weeks was 31.8%. Median time-to-progression was 112 days, median PFS was 112 days and median overall survival was 295 days. Three patients had a maximum reduction of target lesions of between 31% and 60%. The most common adverse events were hypertension, fatigue, diarrhea, rash and proteinuria. The most common grade 3/4 adverse events were hypertension and fatigue [&lt;ulink linkID="1010096" linkType="Reference"&gt;1010096&lt;/ulink&gt;]. In November 2009, further data were presented at the 21st AACR-NCI-EORTC International Conference in Boston, MA. A total of 44 patients were treated with 0.25 mg/kg qd and qod linifanib, of which 4 demonstrated a reduction in CT tumor volume by &amp;gt;/= 30%, and an improved overall survival and PFS. Out of 34 evaluable subjects, 18 had a &amp;gt;/= 40% decrease from baseline in Ktrans (DCE-MRI response), which was not associated with significant improvements in PFS or overall survival [&lt;ulink linkID="1059588" linkType="Reference"&gt;1059588&lt;/ulink&gt;]. In June 2010, further data were presented at the 46th ASCO meeting in Chicago, IL. The objective response rate was 7.9% in patients with Child-Pugh A (n = 38) and was not achieved in Child-Pugh B patients (n = 6). The progression-free rate, media time-to-treatment progression and median overall survival were 34.2%, 5.4 months and 10.4 months, respectively, in Child-Pugh A patients, and 16.7%, 3.7 months and 2.5 months, respectively, in Child-Pugh B patients [&lt;ulink linkID="1105241" linkType="Reference"&gt;1105241&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small cell lung cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;By July 2008, the companies had initiated a phase II trial of linifanib in combination with chemotherapy in patients (expected n = 120) with advanced or metastatic NSCLC [&lt;ulink linkID="925029" linkType="Reference"&gt;925029&lt;/ulink&gt;], [&lt;ulink linkID="1000652" linkType="Reference"&gt;1000652&lt;/ulink&gt;]. The primary endpoint would be  progression-free survival (PFS) [&lt;ulink linkID="1000652" linkType="Reference"&gt;1000652&lt;/ulink&gt;]. The randomized, placebo-controlled, double-blind trial (&lt;ulink linkID="27728" linkType="Protocol"&gt;NCT00716534&lt;/ulink&gt;; M10-301), which took place in the US in 120 patients, aimed to assess the clinical safety and toxicity of high and low doses of linifanib in combination with &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; and &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt;. The trial was expected to complete in March 2011   [&lt;ulink linkID="1028756" linkType="Reference"&gt;1028756&lt;/ulink&gt;], [&lt;ulink linkID="1030118" linkType="Reference"&gt;1030118&lt;/ulink&gt;]. In June 2010, clinical data were presented at the 46th ASCO meeting in Chicago, IL. Patients (n = 139) received linifanib orally, daily under fasting conditions. PFS was seen in both dose cohorts; 0.10 mg/kg (n = 21) and 0.25 mg/kg (n = 27). Median time to PFS was 2.5 and 2.7 months, respectively. Confirmed responses were seen in 2.7% of patients dosed at 0.25 mg/kg. The most common (reported by &amp;gt; 10% patients) drug-related adverse events were hypertension and hand-foot syndrome [&lt;ulink linkID="1104781" linkType="Reference"&gt;1104781&lt;/ulink&gt;]. In June 2011, the trial had been expanded to Australia, Brazil, the Czech Republic, New Zealand, Russia and Singapore. At that time, the trial was estimated to complete in April 2012, and 139 participants were expected to enroll. In August 2011, the trial was recruiting participants. In April 2012, the 145-patient study was completed [&lt;ulink linkID="1030118" linkType="Reference"&gt;1030118&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2007, a randomized, open-label, uncontrolled, parallel-assignment, phase II trial (&lt;ulink linkID="28465" linkType="Protocol"&gt;NCT00517790&lt;/ulink&gt;; M06-880) was initiated in subjects (expected n = 139) with advanced NSCLC in the US, China, Taiwan and Singapore. The primary endpoints were PFS and to determine the efficacy of two different doses of linifanib using RECIST [&lt;ulink linkID="829114" linkType="Reference"&gt;829114&lt;/ulink&gt;]. Enrollment was completed by September 2008 [&lt;ulink linkID="1000652" linkType="Reference"&gt;1000652&lt;/ulink&gt;]. In May 2009, data were presented at the 45th ASCO meeting in Orlando, FL. Results showed the drug was active in NSCLC patients and had an acceptable safety profile [&lt;ulink linkID="1009748" linkType="Reference"&gt;1009748&lt;/ulink&gt;]. In November 2009, further clinical data were presented at the 21st AACR-NCI-EORTC International Conference in Boston, MA. A total of 139 patients  were treated with linifanib at doses of 0.1 mg/kg qd in arm A and 0.25 mg/kg qd in arm B, of which 13 demonstrated a reduction in CT tumor volume by &amp;gt;/= 30%, and an improved overall survival and PFS. Out of 64 evaluable subjects, 25 patients had a &amp;gt;/= 40% decrease from baseline in Ktrans (DCE-MRI response), which was not associated with significant improvements in PFS or overall survival [&lt;ulink linkID="1059588" linkType="Reference"&gt;1059588&lt;/ulink&gt;]. In March 2011, the number of participants was updated to 120. By July 2011, the trial was estimated to complete in December 2011. The trial had also been expanded to Canada and France, while China was no longer listed as a study location. In June 2012, the 140-patient study was completed [&lt;ulink linkID="829114" linkType="Reference"&gt;829114&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In September 2010, Abbott Japan initiated a non-randomized, open-label, phase I trial (&lt;ulink linkID="71508" linkType="Protocol"&gt;NCT01225302&lt;/ulink&gt;; W12-076) of linifanib in combination with &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; and &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt;  as first-line treatment in Japanese patients (estimated n = 12) with advanced or metastatic NSCLC. The study would assess the safety and pharmacokinetics of linifanib, determine the tolerable dose and obtain preliminary efficacy data. The trial completed in June 2012 [&lt;ulink linkID="1220652" linkType="Reference"&gt;1220652&lt;/ulink&gt;]. In September 2011, preliminary data were presented at the European Multidisciplinary Cancer Congress in Stockholm, Sweden. The proportion of patients with partial response (PR) and confirmed PR was 9 and 6 patients, respectively for linifanib in combination with carboplatin and paclitaxel. The Tmax, Cmax and AUC24 values were 2.4 h, 0.25 microg/ml and 3.32 microg.h/ml, respectively for linifanib (7.5 mg), 2.4 h, 0.32 microg/ml and 4.13 microg.h/ml, respectively for linifanib (12.5 mg) and 3.3 h, 0.328 microg/ml and 5.07 microg.h/ml, respectively for the linifanib with carboplatin and cisplatin combination (7.5 mg). Plasma exposure was greater for the combination therapy compared with linifanib monotherapy; and an increase in both Cmax and AUC was observed for linifanib and paclitaxel following co-administration of linifanib with carboplatin and paclitaxel [&lt;ulink linkID="1223580" linkType="Reference"&gt;1223580&lt;/ulink&gt;]. In July 2012, similar data were presented at the Tenth Japanese Society of Medical Oncology Annual Meeting in Osaka, Japan [&lt;ulink linkID="1314297" linkType="Reference"&gt;1314297&lt;/ulink&gt;], [&lt;ulink linkID="1315258" linkType="Reference"&gt;1315258&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;By October 2008, a randomized, placebo-controlled, double-blind, phase II trial (&lt;ulink linkID="35514" linkType="Protocol"&gt;NCT00645177&lt;/ulink&gt;, M10-265, EudraCT 2007-005949-38) of linifanib for first-line metastatic breast cancer  was underway in the US and Mexico [&lt;ulink linkID="957720" linkType="Reference"&gt;957720&lt;/ulink&gt;], [&lt;ulink linkID="1000652" linkType="Reference"&gt;1000652&lt;/ulink&gt;]. Patients (expected n = 102) would receive &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; with po linifanib qd or paclitaxel with a placebo. The primary endpoint would be  PFS [&lt;ulink linkID="1000652" linkType="Reference"&gt;1000652&lt;/ulink&gt;], [&lt;ulink linkID="1028756" linkType="Reference"&gt;1028756&lt;/ulink&gt;], [&lt;ulink linkID="1030114" linkType="Reference"&gt;1030114&lt;/ulink&gt;].  The trial completed in March 2010. The open-label, lead-in portion of the trial had enrolled 10 patients; the randomized portion of the trial had not been initiated [&lt;ulink linkID="1030114" linkType="Reference"&gt;1030114&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October  2008, a phase II trial for  second-line metastatic CRC was underway. Patients (expected n = 102) would receive either FOLFOX6 chemotherapy plus linifanib or  FOLFOX6 chemotherapy plus &lt;ulink linkID="8047" linkType="Drug"&gt;Avastin&lt;/ulink&gt;. The primary endpoint would be  PFS [&lt;ulink linkID="1000652" linkType="Reference"&gt;1000652&lt;/ulink&gt;]. The randomized, open-label study (&lt;ulink linkID="45742" linkType="Protocol"&gt;NCT00707889&lt;/ulink&gt;, M10-300, EudraCT: 2007-007081-38) which took place in the US and Australia, in 135 patients, would administer oral  linifanib qd at high (12.5 mg) and low (7.5 mg) doses. The trial was expected to complete in March 2011 [&lt;ulink linkID="1028756" linkType="Reference"&gt;1028756&lt;/ulink&gt;], [&lt;ulink linkID="1030112" linkType="Reference"&gt;1030112&lt;/ulink&gt;]. In February 2011, recruitment had completed; a total of 161 participants had been enrolled. The trial had also been expanded to Canada, Brazil, Korea, New Zealand, Russia and Europe. The study was completed in May 2012 [&lt;ulink linkID="1030112" linkType="Reference"&gt;1030112&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Renal cell carcinoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In July 2007, a non-randomized, open-label, uncontrolled, phase II trial (&lt;ulink linkID="39086" linkType="Protocol"&gt;NCT00486538&lt;/ulink&gt;; M06-882) was initiated in subjects (expected n = 53) with advanced RCC, who had previously been treated with &lt;ulink linkID="12973" linkType="Drug"&gt;sunitinib&lt;/ulink&gt;, in the US and Canada. The primary endpoint was to evaluate the efficacy and tolerability of linifanib and the objective response rate to treatment. The trial was completed in  June 2012 [&lt;ulink linkID="809181" linkType="Reference"&gt;809181&lt;/ulink&gt;]; enrollment was completed by December 2008  [&lt;ulink linkID="1000652" linkType="Reference"&gt;1000652&lt;/ulink&gt;]. In May 2009, interim data were reported at the 45th ASCO meeting in Orlando, FL. Objective response rate was 9.4% by central imaging. Median time-to-progression was 4.9 months, and median PFS was 5.4 months. Median overall survival was 11.6 months, although data were immature.  One patient had a partial response. Adverse events &amp;gt;/= grade 3 included hypertension, fatigue, diarrhea and hand-foot syndrome; 31 patients required dose reductions, and seven discontinued treatment due to adverse events. An alternative dosing strategy was to be considered for future studies [&lt;ulink linkID="1006990" linkType="Reference"&gt;1006990&lt;/ulink&gt;]. In November 2009, further data were presented at the 21st AACR-NCI-EORTC International Conference in Boston, MA. A total of 53 patients who had received prior sunitinib therapy and progressed, were treated with 0.25 mg/kg qd linifanib within 100 days of enrollment, of which 10 demonstrated a reduction in CT tumor volume by &amp;gt;/= 30%, and an improved overall survival and PFS. Out of 17 evaluable subjects, 12 had a &amp;gt;/= 40% decrease from baseline in Ktrans (DCE-MRI response), which was not associated with significant improvements in PFS or overall survival [&lt;ulink linkID="1059588" linkType="Reference"&gt;1059588&lt;/ulink&gt;]. In June 2010, similar data were presented at the 46th ASCO meeting in Chicago, IL. The drug demonstrated antitumor activity in RCC patients. Common adverse events were moderate, manageable and similar to those observed for other multi-targeted tyrosine kinase inhibitors. Significant dose modification was required for the 0.25 mg/kg dose; future trials would start at 17.5 mg/day [&lt;ulink linkID="1105210" linkType="Reference"&gt;1105210&lt;/ulink&gt;]. In June 2011,  data were presented at the 47th ASCO meeting in Chicago, IL. In the study, the biomarkers CA 125, CYFRA 21.1, TIMP-1 and ProGRP were correlated with increased PFS. CA 125, CA 15-3, CYFRA 21.1 and TIMP-1 were also correlated with overall survival. Based on these results, researchers concluded that further investigation of  linifanib for RCC should take the  biomarker-identified subset of patients into consideration [&lt;ulink linkID="1195164" linkType="Reference"&gt;1195164&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumors&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In April 2009, clinical data were presented at the 100th AACR meeting in Denver, CO from three phase II studies for HCC, NSCLC and RCC. Of the 17 patients who had been fully evaluated,  in those that had a PET response, 2 had a partial response, 5 had stable disease and 2 experienced disease progression. In those that did not show a PET response, 0 had a partial response, 4 had stable disease and 4 experienced disease progression [&lt;ulink linkID="997862" linkType="Reference"&gt;997862&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In May 2011, a randomized, open-label, crossover-assignment, pharmacokinetics, phase I trial (&lt;ulink linkID="80408" linkType="Protocol"&gt;NCT01381341&lt;/ulink&gt;; M11-817) to compare the relative bioavailability of two clinical formulations of linifanib began in patients (expected n = 12) in the US with  advanced or metastatic solid tumors. The trial completed in December 2011 [&lt;ulink linkID="1217918" linkType="Reference"&gt;1217918&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2008, a phase I trial (&lt;ulink linkID="41044" linkType="Protocol"&gt;NCT00718380&lt;/ulink&gt;; M10-227) was initiated in patients (n = 18) with solid tumors in Japan. In November 2009, data were presented at the 21st AACR-NCI-EORTC International Conference in Boston, MA. Confirmed partial responses were seen in two patients and  one had an unconfirmed partial response. The Cmax and AUC figures were similar to those found in non-Japanese studies at comparable doses [&lt;ulink linkID="1059712" linkType="Reference"&gt;1059712&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2008, phase I data were presented at the 236th ACS National Meeting in Philadelphia, PA. In 16 subjects with a range of cancers, linifanib produced 2 partial responses and 12 incidents of stable disease [&lt;ulink linkID="930487" linkType="Reference"&gt;930487&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, clinical data were presented at the 18th EORTC-NCI-AACR meeting in Prague, Czech Republic. In the phase I study of nine patients with solid tumors, six had received 10 mg/day, and three had received 0.25 mg/kg/day. Toxicities included fatigue, asthenia, myalgia, skin rash, hand foot syndrome, hypertension, proteinuria and mouth irritation. Plasma clearance was 2.8  l/h, with a corresponding mean half-life of 16  h. Drug accumulation was not significant with continuous dosing, and the target AUC (4.9 microg.h/ml) for activity based on preclinical models was reached with daily dosing of 10 mg. Cytochrome p450 enzymes played a role in metabolism. Five of the six patients on 10 mg/day had stable disease, with CT scan evidence of tumor necrosis [&lt;ulink linkID="739420" linkType="Reference"&gt;739420&lt;/ulink&gt;]. In June 2007, at the 43rd ASCO meeting in Chicago, IL, it was disclosed that a further nine patients had been added to the group receiving 0.25 mg/kg/day and three patients were administered with 0.3 mg/kg/day.  Partial responses were seen in two patients, while 12 had disease control. The oral clearance and half-life of the drug were 2.8 +/- 1.2 l/h and 16.9 +/- 5 h, respectively. The patients' mean peak plasma VEGF levels were increased  from baseline, and circulating endothelial progenitors (CEPs) and circulating endothelial cells (CECs) were reduced in most patients by day 15. It was reported that 0.25 mg/kg/day was the recommended dose of linifanib, which has shown promising clinical activity in NSCLC [&lt;ulink linkID="796317" linkType="Reference"&gt;796317&lt;/ulink&gt;]. In October 2007, these data were presented at the Fifth CHI Discovery on Target Conference in Boston, MA [&lt;ulink linkID="844994" linkType="Reference"&gt;844994&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2006, a phase I trial involving patients with refractory or relapsed AML or MDS began at the MD Anderson Cancer Center. The study was to identify the MTD of linifanib when either administered alone or in combination with &lt;ulink linkID="70185" linkType="Drug"&gt;cytarabine&lt;/ulink&gt;;  recruitment of 50 patients was planned [&lt;ulink linkID="685691" linkType="Reference"&gt;685691&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, an IND for linifanib had been filed  [&lt;ulink linkID="596245" linkType="Reference"&gt;596245&lt;/ulink&gt;]; the study's IRB review had taken place and approval had been received by August 2005 [&lt;ulink linkID="685691" linkType="Reference"&gt;685691&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous trials&lt;/subtitle&gt;In June 2011, data from  Chinese and Japanese analyses  were presented from two phase I and three phase II trials, and three phase I, one phase II and one phase III trial, respectively  at the 47th ASCO meeting in Chicago, IL.  The trials evaluated the impact of ethnicity on safety, tolerability and pharmacokinetics of the drug. Ethnicity was not a significant factor influencing the exposure-safety response relationship for any of the tested adverse events [&lt;ulink linkID="1196527" linkType="Reference"&gt;1196527&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2009, preclinical data were presented at the 21st AACR-NCI-EORTC International Conference in Boston, MA. Linifanib (6.25, 12.5 and 25 mg/kg/day) was evaluated  in combination with different cytotoxic therapies in various cancer cell lines, and demonstrated significant antitumor efficacy in a dose-responsive manner and good tolerability in all models tested. Linifanib at 6.25 mg/kg/day dose was more efficacious than cytotoxic treatment alone. As a monotherapy, linifanib was also well tolerated and demonstrated antitumor activity [&lt;ulink linkID="1059645" linkType="Reference"&gt;1059645&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2009, data were presented at the 100th AACR meeting in Denver, CO. In vitro, linifanib demonstrated nanomolar inhibition and exhibited apoptotic and antiproliferative effects in Ba/F3 FLT-3 ITD mutant cells. The compound also inhibited FLT3 phosphorylation in FLT3 1TD mutant cell lines both in vitro and in vivo, following daily dosing at 40 mg/kg [&lt;ulink linkID="997427" linkType="Reference"&gt;997427&lt;/ulink&gt;]. Further data presented showed linifanib inhibited CSF-1 primed release and reduced CSF-1 primed release TNF-alpha to non-primed levels [&lt;ulink linkID="993970" linkType="Reference"&gt;993970&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, preclinical data were presented at the 50th ASH meeting in San Francisco, CA. Linifanib demonstrated an increase in apoptosis in the Ba/F3 Flt-3 ITD mutant cells and in SCID mice, linifanib had slower median tumor progression than control, with median survival of 6.2 weeks [&lt;ulink linkID="966411" linkType="Reference"&gt;966411&lt;/ulink&gt;]. A combination of linifanib and &lt;ulink linkID="17625" linkType="Drug"&gt;vorinostat&lt;/ulink&gt; displayed apoptotic effect in acute myeloid leukemia cell lines with FLT3 mutations [&lt;ulink linkID="967269" linkType="Reference"&gt;967269&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, preclinical data were presented at the 99th AACR annual meeting in San Diego, CA. Linifanib inhibited tumor microvessel function in a rat glioma model, demonstrating a rapid onset of action and prolonged effect [&lt;ulink linkID="893503" linkType="Reference"&gt;893503&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007,  data were presented at the 49th ASH meeting in Atlanta, GA [&lt;ulink linkID="860006" linkType="Reference"&gt;860006&lt;/ulink&gt;]. Linifanib treatment prolonged survival in mouse models of mutant-Flt3 leukemia [&lt;ulink linkID="857907" linkType="Reference"&gt;857907&lt;/ulink&gt;]. It showed activity against AML cells in vitro and in vivo [&lt;ulink linkID="857908" linkType="Reference"&gt;857908&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, data were presented at the 19th AACR-NCI-EORTC International Conference in San Francisco, CA. Linifanib as a monotherapy demonstrated potent antitumor efficacy in the LuCap 23.1 osteoblastic model with a decrease in serum PSA and in AIC.  The compound was also effective in the PC-3M-luciferase osteolytic bone metastasis model. Neither &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; or &lt;ulink linkID="2765" linkType="Drug"&gt;zoledronic&lt;/ulink&gt; acid alone had an observable effect on tumor burden, in combination with linifanib  both demonstrated a significant reduction in burden  as determined by bioluminescent imaging. The drug was well-tolerated as a monotherapy and in combination in both models [&lt;ulink linkID="845602" linkType="Reference"&gt;845602&lt;/ulink&gt;]. Further data presented showed that the compound also had efficacy in HCC, RCC and prostate xenografts [&lt;ulink linkID="845596" linkType="Reference"&gt;845596&lt;/ulink&gt;]. Pharmacokinetic comparisons were carried out in Asian and Caucasian populations. Data were taken from two ongoing dose-escalation trials in which patients received daily linifanib for 21 days. Doses started at 10 mg qd.  No evidence of any difference in pharmacokinetic parameters was observed between the two populations. The Tmax was approximately 3 h and elimination half life was approximately 14 h in both groups [&lt;ulink linkID="845206" linkType="Reference"&gt;845206&lt;/ulink&gt;].  Further data presented showed that the bioavailability of an oral tablet  and an oral solution were similar [&lt;ulink linkID="845207" linkType="Reference"&gt;845207&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2007, preclinical data on a series of pyrimidodiazepine analogs of linifanib were presented at the 234th ACS meeting in Boston, MA. Compounds were generated with single-figure nanomolar IC50 values for phosphorylation of Kdr. An example compound demonstrated IC50 values of 3, 15, 2 and 11 nM against Kdr, Flt1, Flt3 and cKit, but did not inhibit FGFR, Fyn, Lck, Lyn and Src [&lt;ulink linkID="819772" linkType="Reference"&gt;819772&lt;/ulink&gt;]. SAR data on a series of aminopyrazolopyridine urea analogs were also presented. An example compound inhibited phosphorylation of purified Kdr and cell-based Kdr with IC50 values of 4.6 and 1.8 nM. It inhibited estradiol-induced uterine edema in aged Balb/c mice by 79% after dosing at 10 mg/kg po. Pharmacokinetic data were collected after dosing at 3 mg/kg iv (t1/2 = 0.6h, Vd = 0.66 l/kg, Cl= 12.7 ml/min.kg) and 10 mg/kg po (F= 71%, AUC = 25 microM.h) in CD-1 mice. It demonstrated IC50 values of 7, 4 and 7 nM against  Flt1, Flt3 and cKit, but did not inhibit Fyn or Src [&lt;ulink linkID="819673" linkType="Reference"&gt;819673&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2006, preclinical data on a series of 3-amino benzo(d)isoxazoles  related to linifanib were presented at the 232nd ACS Meeting in San Francisco, CA. Selected compounds exhibited in vitro inhibitory activity against VEGF and PDGF family receptor tyrosine kinases, including one compound with IC50 values of 11, 16, 19, 56, 30 and 130 nm against VEGF-2, VEGF-1, Flt3, cKit, CSF-1R and PDGFR-b, respectively. In vivo (n = 10 per group) the compound exhibited tumor growth inhibition of 91 and 81% at doses of 30 and 10 mg/kg/day, respectively, in an HT1080 mouse model. The compound also demonstrated 97% inhibition of VEGF-mediated uterine edema   at a dose of 10 mg/kg/day po (n = 6), and      had a CL of 1.7 l/h.kg, Vd of 2.5 l/kg,  bioavailability of &amp;gt; 100% and AUC of 30.6 (po, microM.h/ml) [&lt;ulink linkID="687397" linkType="Reference"&gt;687397&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt;In December 2005,  data were presented at the 47th ASH meeting in Atlanta, GA. In vitro viability assays showed that linifanib inhibited the growth of  MV-4-11 human AML cells and BAF3-ITD murine B-cells at an IC50 value of 10 nM. The compound induced apoptosis, caspase-3 activation, and PARP cleavage after 48 h. Complete regression of MV-4-11 tumors was observed in SCID mice treated with oral linifanib at 20 and 40 mg/kg/day. No adverse effects were detected in the peripheral blood counts, bone marrow, spleen or liver. Mice that received linifanib the day after injection of AML cells remained tumor-free for over 2 months [&lt;ulink linkID="641017" linkType="Reference"&gt;641017&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, preclinical data on linifanib were presented at the 96th AACR meeting in Anaheim, CA. Studies showed linifanib to be a potent inhibitor of all  VEGF and PDGF receptor tyrosine kinase (RTK) family members, having in vitro IC50 values at cloned KDR, FLT1, FLT3, FLT4, PDGFRbeta, CSF-1R, KIT and TIE2 receptor domains of 4, 3, 4, 190, 66, 3, 14 and 179 nM, respectively. Selectivity was demonstrated by IC50 values of greater than 38 microM at non-related RTKs, and greater than 1 microM at serine/threonine kinases. In cellular assays of RTK phosphorylation, linifanib inhibited KDR, PDGFRbeta, KIT and CSF-1R in stimulated 3T3 cells with IC50 values of 2, 4, 31 and 10 nM, respectively, and inhibited KDR in VEGF-stimulated human primary endothelial cells  with an IC50 value of 0.2 nM. Linifanib showed only weak inhibition of the growth of cancer cells whose proliferation is not driven by VEGF or PDGF RTKs (IC50 ~ 1.3 to 6.8 microM in HT29 and MDA435 cells). However, in MV-4-11 and Kasumi-1 cells, which constitutively overexpress FLT3 and KIT, respectively, IC50 values were 11 and 4 nM. In vivo, linifanib is effective when given orally in murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and VEGF and bFGF-induced angiogenesis (&amp;gt; 50% inhibition at 15 mg/kg, po, in mouse cornea). In murine xenograft tumor growth studies, linifanib exhibited efficacy against human fibrosarcomas (HT1080) and human breast (MX1), colon (DLD1), and small cell lung carcinoma (H526) with ED50 values of 3 to 10 mg/kg/day po. Efficacy was also seen in mouse orthotopic breast and prostate cancer and glioma models, in which linifanib caused greater than 50% tumor growth inhibition, and regression in epidermoid carcinoma and leukemia models. Pharmacokinetic analysis of murine tumor growth studies suggested that efficacy correlated more strongly with time over a threshold value, such as the cellular IC50 for KDR corrected for plasma protein binding, than with plasma AUC or Cmax [&lt;ulink linkID="593433" linkType="Reference"&gt;593433&lt;/ulink&gt;], [&lt;ulink linkID="597067" linkType="Reference"&gt;597067&lt;/ulink&gt;]. Further studies presented at the 96th AACR meeting in Anaheim, CA,  investigated linifanib in leukemia. In an ex vivo model of AML, where MV411 cells were introduced into human blood to mimicking the clinical setting, linifanib inhibited FLT3 phosphorylation with an approximate IC50 value of 100 nM. In vivo, linifanib showed efficacy against a variety of sarcoma, colon, breast, prostate, brain, lung and kidney cell line xenografts. Linifanib also inhibited FLT3 and caused significant regression of established MV411 xenograft in SCID mice [&lt;ulink linkID="594748" linkType="Reference"&gt;594748&lt;/ulink&gt;]. A third study compared linifanib activity to that of a number of other RTK inhibitors in  development. Linifanib, &lt;ulink linkID="11460" linkType="Drug"&gt;Gleevec&lt;/ulink&gt;, &lt;ulink linkID="39209" linkType="Drug"&gt;AG-013736&lt;/ulink&gt;, &lt;ulink linkID="40735" linkType="Drug"&gt;CHIR-258&lt;/ulink&gt;, &lt;ulink linkID="29831" linkType="Drug"&gt;BAY-43-9006&lt;/ulink&gt;  and &lt;ulink linkID="12973" linkType="Drug"&gt;SU-11248&lt;/ulink&gt; were tested for inhibition of CSF-1R signaling in enzymatic and cellular assays.  Linifanib showed excellent CSF-1R inhibition in both the enzyme and cell-based assays [&lt;ulink linkID="596245" linkType="Reference"&gt;596245&lt;/ulink&gt;], [&lt;ulink linkID="597067" linkType="Reference"&gt;597067&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In May 2009, the EMEA's pediatric committee agreed a pediatric investigation plan for the drug in the area of oncology [&lt;ulink linkID="1015559" linkType="Reference"&gt;1015559&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1074105" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1074105" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1074105" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1074105" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1074105" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1074105" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1074105" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1074105" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1074105" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="829114" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030118" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030118" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030114" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="CL">Chile</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2012-07-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2007-07-09T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-01-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-01-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030118" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-01-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-01-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="829114" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1220662" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="829114" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030118" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="809181" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="809181" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030118" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-01-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-01-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-01-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="X2">Asia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="829114" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-01-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2007-07-09T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="XH">Far East</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-01-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-01-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030114" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-01-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-01-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2012-12-27T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2011-02-04T00:00:00.000Z</StatusDate><Source id="1074723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CL">Chile</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2011-02-04T00:00:00.000Z</StatusDate><Source id="1074723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2011-02-04T00:00:00.000Z</StatusDate><Source id="1074723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2011-02-04T00:00:00.000Z</StatusDate><Source id="1074723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2011-02-04T00:00:00.000Z</StatusDate><Source id="1074723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2011-02-04T00:00:00.000Z</StatusDate><Source id="1074723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2011-02-04T00:00:00.000Z</StatusDate><Source id="1074723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2011-02-04T00:00:00.000Z</StatusDate><Source id="1074723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2009-10-31T00:00:00.000Z</StatusDate><Source id="1074723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2009-10-31T00:00:00.000Z</StatusDate><Source id="1074723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2009-10-31T00:00:00.000Z</StatusDate><Source id="1074723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2009-10-31T00:00:00.000Z</StatusDate><Source id="1074723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="EG">Egypt</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2011-02-04T00:00:00.000Z</StatusDate><Source id="1074723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2011-07-19T00:00:00.000Z</StatusDate><Source id="829114" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2007-08-31T00:00:00.000Z</StatusDate><Source id="829114" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2011-06-13T00:00:00.000Z</StatusDate><Source id="1030118" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2011-06-13T00:00:00.000Z</StatusDate><Source id="1030118" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2011-06-13T00:00:00.000Z</StatusDate><Source id="1030118" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2011-06-13T00:00:00.000Z</StatusDate><Source id="1030118" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2011-02-23T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2011-02-23T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2011-02-23T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2011-02-23T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2011-02-23T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2011-02-23T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2008-10-28T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2008-10-28T00:00:00.000Z</StatusDate><Source id="1030112" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2011-07-19T00:00:00.000Z</StatusDate><Source id="829114" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2011-07-07T00:00:00.000Z</StatusDate><Source id="1220662" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2007-07-18T00:00:00.000Z</StatusDate><Source id="809181" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="X2">Asia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2007-08-31T00:00:00.000Z</StatusDate><Source id="829114" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2008-07-31T00:00:00.000Z</StatusDate><Source id="1030114" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2007-07-18T00:00:00.000Z</StatusDate><Source id="809181" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2008-07-31T00:00:00.000Z</StatusDate><Source id="1030114" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2011-06-13T00:00:00.000Z</StatusDate><Source id="1030118" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-04-16T00:00:00.000Z</StatusDate><Source id="596245" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2006-01-09T00:00:00.000Z</StatusDate><Source id="685691" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2006-01-09T00:00:00.000Z</StatusDate><Source id="685691" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2007-06-26T00:00:00.000Z</StatusDate><Source id="808616" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2007-06-26T00:00:00.000Z</StatusDate><Source id="808616" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2008-12-26T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2008-12-26T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2007-08-31T00:00:00.000Z</StatusDate><Source id="827892" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2007-07-18T00:00:00.000Z</StatusDate><Source id="809181" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2007-08-31T00:00:00.000Z</StatusDate><Source id="829114" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2007-08-31T00:00:00.000Z</StatusDate><Source id="827892" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2007-08-31T00:00:00.000Z</StatusDate><Source id="829114" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="XD">North America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2007-08-31T00:00:00.000Z</StatusDate><Source id="827892" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="X2">Asia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2007-08-31T00:00:00.000Z</StatusDate><Source id="827892" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2008-10-14T00:00:00.000Z</StatusDate><Source id="957720" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2008-10-14T00:00:00.000Z</StatusDate><Source id="957720" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2010-09-28T00:00:00.000Z</StatusDate><Source id="1220652" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="13601">Abbott Laboratories</OwnerCompany><Country id="EU">EU</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2013-02-28T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="13601">Abbott Laboratories</OwnerCompany><Country id="EU">EU</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2007-12-20T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="13601">Abbott Laboratories</OwnerCompany><Country id="EU">EU</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2007-11-08T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072507">AbbVie Inc</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myelogenous leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2007-10-23T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072507">AbbVie Inc</OwnerCompany><Country id="US">US</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2007-05-23T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00510"><Name>CSF-1</Name><SwissprotNumbers><Swissprot>P07333</Swissprot><Swissprot>P09581</Swissprot><Swissprot>P13369</Swissprot><Swissprot>Q00495</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00762"><Name>Flt3 tyrosine kinase</Name><SwissprotNumbers><Swissprot>P36888</Swissprot><Swissprot>Q00342</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01208"><Name>Kit tyrosine kinase</Name><SwissprotNumbers><Swissprot>O97799</Swissprot><Swissprot>P05532</Swissprot><Swissprot>P10721</Swissprot><Swissprot>P43481</Swissprot><Swissprot>Q08156</Swissprot><Swissprot>Q28317</Swissprot><Swissprot>Q28889</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01938"><Name>VEGF-1 receptor</Name><SwissprotNumbers><Swissprot>P17948</Swissprot><Swissprot>P35969</Swissprot><Swissprot>P53767</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01939"><Name>VEGF-2 receptor</Name><SwissprotNumbers><Swissprot>O08775</Swissprot><Swissprot>P35918</Swissprot><Swissprot>P35968</Swissprot><Swissprot>P52583</Swissprot><Swissprot>Q8AXB3</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01940"><Name>VEGF-3 receptor</Name><SwissprotNumbers><Swissprot>P35916</Swissprot><Swissprot>P35917</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="13601">Abbott Laboratories</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1ccc(c(c1)NC(=O)Nc2ccc(cc2)c3cccc4c3c(n[nH]4)N)F</Smiles><Smiles>c1cc(ccc1C2=Nc3c(ncnc3NCC2)N)NC(=O)Nc4cc(ccc4F)C(F)(F)F</Smiles><Smiles>COc1ccc(c2c1onc2N)c3ccc(cc3)NC(=O)Nc4cccc(c4)C(F)(F)F</Smiles><Smiles>Cc1cccc(c1)NC(=O)Nc2ccc(cc2)c3cncc4c3c(nn4C)N</Smiles></StructureSmiles><Deals><Deal id="109880" title="Abbott and Genentech to develop AB-263 and ABT-869  "/></Deals><PatentFamilies><PatentFamily id="1218800" number="WO-2007050574" title="Formulation comprising a drug of low water solubility and method of use thereof"/><PatentFamily id="1306728" number="WO-2009155324" title="PlGF-1 assay and kits and components thereof"/><PatentFamily id="1818223" number="WO-2009050291" title="Solid dispersion product of N-aryl urea-based drugs"/><PatentFamily id="1827606" number="WO-2009052226" title="Crystalline indazole-derived chemotherepeutic"/><PatentFamily id="2107867" number="WO-2008055965" title="Melt-processed imatinib dosage form"/><PatentFamily id="2679759" number="WO-2014022975" title="N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methyl phenyl)carbamide and preparation method for intermediate thereof"/><PatentFamily id="2759475" number="US-08759538" title="Crystalline chemotherapeutic"/><PatentFamily id="3150090" number="WO-2014117075" title="Trans-arterial drug delivery"/><PatentFamily id="3353880" number="WO-2009117277" title="Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use"/><PatentFamily id="338521" number="WO-2009052230" title="Crystalline chemotherapeutic"/><PatentFamily id="375432" number="WO-2011140234" title="Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor"/><PatentFamily id="4060017" number="WO-2018090974" title="Compound having anti-cancer effect, and preparation method therefor and use thereof"/><PatentFamily id="419985" number="WO-2009052229" title="Crystalline chemotherapeutic"/><PatentFamily id="4450475" number="CN-109464443" title="New application of linifanib"/><PatentFamily id="445609" number="WO-2009100176" title="Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor"/><PatentFamily id="553254" number="WO-2008070301" title="Predicting lung cancer survival using gene expression"/><PatentFamily id="626731" number="US-20070173538" title="Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye"/><PatentFamily id="855730" number="WO-2009052231" title="Crystalline chemotherapeutic"/><PatentFamily id="937966" number="WO-2004113304" title="Indazole, benzisoxazole, and benzisothiazole kinase inhibitors"/><PatentFamily id="938188" number="WO-2009052225" title="Crystalline chemotherapeutic"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AbbVie Inc" id="1072507"/><CountAsOwner>10</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>10</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Acebright Pharmaceuticals Group Co Ltd" id="1078168"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="3D Medicines" id="1120744"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"/><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alcon Inc" id="18478"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Sciences" id="23863"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Washington University in St Louis" id="26113"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>